Phase 2a Protocol for the Phase 2 HIV study

A Phase II Study Testing the Activity and Safety in successfully ART-Treated Subjects Infected with HIV in Combination with ART Followed by ART Interruption.

Study Design: The study design is identical to the Phase I study except that after the fourth dose patients will begin a drug treatment interruption period while receiving additional immunizations during that period. This provides an opportunity to assess the impact of the Arcelis therapy on viral load. Current status: Argos has received regulatory approval for this study and is actively accruing patients.

• biomaterial type
• Homo sapiens

created over 16 years ago (2 March 2009)    last modified over 12 years ago (26 November 2012)   [ RDF ]   [ RelFinder ]